Innovent Biologics H1 Revenue RMB8.618 Billion, Up 44.8%; Net Profit RMB1.253 Billion

Innovent Biologics released its interim results on August 25. For the first half of 2026, the company's total revenue reached RMB8.618 billion, representing a year-on-year increase of 44.8%. Product revenue amounted to RMB8.201 billion, up 56.7% from the same period last year.

On an IFRS basis, the company recorded a net profit of RMB1.253 billion for the first half, a 50.2% increase year on year. This interim net profit already surpasses the company's total net profit for the full year of 2025.